These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 27466480)
1. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. Karagiannis AK; Girio-Fragkoulakis C; Nakouti T Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480 [TBL] [Abstract][Full Text] [Related]
2. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Trimboli P; Lauretta R; Barnabei A; Valabrega S; Romanelli F; Giovanella L; Appetecchia M Int J Biol Markers; 2018 May; 33(2):156-160. PubMed ID: 29707993 [TBL] [Abstract][Full Text] [Related]
3. Negative predictive value of procalcitonin in medullary thyroid carcinoma. Lim SK; Guéchot J; Vaubourdolle M Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393 [TBL] [Abstract][Full Text] [Related]
4. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Trimboli P; Giovanella L Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697 [TBL] [Abstract][Full Text] [Related]
5. Clinical performance of calcitonin and procalcitonin Elecsys Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633 [TBL] [Abstract][Full Text] [Related]
6. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen. Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679 [TBL] [Abstract][Full Text] [Related]
8. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. Giovanella L; Imperiali M; Piccardo A; Taborelli M; Verburg FA; Daurizio F; Trimboli P Eur J Clin Invest; 2018 Jun; 48(6):e12934. PubMed ID: 29635700 [TBL] [Abstract][Full Text] [Related]
9. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Trimboli P; Seregni E; Treglia G; Alevizaki M; Giovanella L Endocr Relat Cancer; 2015 Jun; 22(3):R157-64. PubMed ID: 25934688 [TBL] [Abstract][Full Text] [Related]
11. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163 [TBL] [Abstract][Full Text] [Related]
12. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280 [TBL] [Abstract][Full Text] [Related]
13. Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma. Kratzsch J; Willenberg A; Frank-Raue K; Kempin U; Rocktäschel J; Raue F Clin Chem Lab Med; 2021 Oct; 59(11):1861-1868. PubMed ID: 34256421 [TBL] [Abstract][Full Text] [Related]
14. Clinical challenges with calcitonin-negative medullary thyroid carcinoma. Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. Raue F; Frank-Raue K Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384 [TBL] [Abstract][Full Text] [Related]
16. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker. Zhan S; Li J; Wang T; Ge W Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896 [TBL] [Abstract][Full Text] [Related]
17. Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows. Censi S; Di Stefano M; Repaci A; Benvenuti T; Manso J; Pagotto U; Iacobone M; Barollo S; Bertazza L; Galuppini F; Benna C; Pennelli G; Plebani M; Faggian D; Colombo C; Fugazzola L; Mian C Front Endocrinol (Lausanne); 2021; 12():754565. PubMed ID: 34721303 [TBL] [Abstract][Full Text] [Related]
18. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer. Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598 [TBL] [Abstract][Full Text] [Related]
19. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Bolko P; Manuszewska-Jopek E; Michałek K; Waśko R; Jaskuła M; Sowiński J Arch Immunol Ther Exp (Warsz); 2003; 51(6):415-9. PubMed ID: 14692663 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]